61 results about "Neuritis" patented technology

The invention provides an extraction and detection method of a day lily active matter and application of the day lily active matter in anti-neuritis. Hemerocallis fulva contains various bioactive substances including flavone, polysaccharide and saponin, and the substances have potential application value in the fields of medicines and health care products. The invention provides a method for extracting the active components step by step, and rapid identification and detection are carried out by utilizing technologies such as fluorescence and ultraviolet-visible spectrophotometry. In addition, the invention also develops a detection method for evaluating the anti-neuritis effect of the active substances. Lipopolysaccharide (LPS) is used for stimulation to establish an inflammation model, day lily active substances are added, and the active substances are found to be capable of remarkably inhibiting generation and release of inflammatory factors and promoting growth and differentiation of neurons. Scientific basis is provided for developing new neuritis treatment methods, related drugs and the like.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The application relates to the technical field of targeted drugs, in particular to an organic compound and application of the organic compound in preparation of a PET probe for targeting 18kDa translocation protein and in pharmacy. 18 Or F. Compared with a conventional PET probe, the organic compound has the targeting TSPO characteristic, can be used for preparing the PET probe for targeting TSPO, is stable in in-vivo plasma metabolism, has lower non-specific uptake, and can be used for diagnosis, scientific research and drug preparation of neuroinflammation.

Provided is a composition for preparing a medicament for treating diabetic peripheral neuropathy. The pharmaceutical composition comprises cobra venom phospholipase A2, or a combination of cobra venom phospholipase A2 and at least one additional drug for treating diabetic peripheral neuropathy. The diabetic peripheral neuropathy is characterized by a slowdown in motor nerve conduction velocity and / or sensory nerve conduction velocity of a patient, and / or hypoesthesia or loss of sensation in both lower limbs. The pharmaceutical composition can be used to ameliorate the clinical symptoms described above in patients with diabetic peripheral neuropathy, and belongs to the field of biopharmaceuticals.

The invention belongs to the technical field of medicines, and particularly relates to a phenanthroindolizidine alkaloid compound and application thereof. The invention discloses two kinds of phenanthroindolizidine alkaloid compounds, namely (-)-(R)-13a alpha-secoxanthin and (-)-(R)-13a alpha-6-O-desmylanthin, which are derived from a traditional Chinese medicine cynanchum atratum, and discloses the obvious anti-neuritis activity of the phenanthroindolizidine alkaloid compounds for inhibiting the generation of nitric oxide. Animal experiments prove that by intraperitoneal injection of the (-)-(R)-13a alpha-secoxanthin and the (-)-13a alpha-6-O-desmylanthin, the autonomous movement ability of a depression mouse is remarkably improved, the exploration behavior of the mouse is recovered, the anxiety symptom of the mouse is relieved, and the despair behavior of the mouse is relieved. The invention provides a new lead compound for research and development of new antidepressant drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to application of Chi3l1 as a target spot in preparation of a medicine for preventing or treating secondary brain injury after cerebral hemorrhage. By integrating space transcriptomics and a mononuclear RNA sequencing technology, the spatial heterogeneity and cell type specificity of gene expression in ICH afterbrain tissue are deeply analyzed, a group of astrocyte subgroups AST1 with neuritis existing around hematoma in the acute stage after cerebral hemorrhage is identified, Chi3l1 is determined as a key inflammatory effect factor of the AST1 subgroups, and the AST1 subgroups with neuritis are used as the key inflammatory effect factor of the AST1 subgroups. And the influence of the gene on the phenotypic transformation of astrocytes and microglial cells is verified. The discovery provides an important theoretical basis for developing a treatment strategy of targeting Chi3l1, and is expected to improve neuroinflammatory response and neurological dysfunction after ICH by regulating and controlling expression of the AST1 subgroup and Chi3l1, and opens up a new direction for treatment of ICH.

The present invention discloses a crotan-type diterpene compound, its preparation method, and application, relating to the field of pharmaceutical technology. The present invention extracts a crotan-type diterpene compound of novel structure from sage. The compound has significant inhibitory activity against neuronal inflammation, exhibits excellent anti-neuritis effects, and significantly inhibits inflammatory mediators. It can be developed as a therapeutic drug for neurodegenerative diseases.

The invention provides a cassane diterpenoid compound and an application of the cassane diterpenoid compound in preparation of an anti-neuroinflammation medicine. Six novel cassane diterpenoid compounds are separated from mysorethorn, and a preparation method of the six compounds is provided. According to the present invention, the inhibition effect of lipopolysaccharide (LPS)-induced BV-2 microglial cells on NO production is determined, and the six compounds have anti-neuroinflammatory activity, and particularly, the compounds 4 and 5 have good anti-inflammatory effect compared with other compounds, and have the potential of anti-neuroinflammatory drug preparation.

The invention provides a dendrobium officinale exosome composition loaded with miR-146a and miR-124 as well as a preparation method and application of the dendrobium officinale exosome composition loaded with miR-146a and miR-124. According to the present invention, the dendrobium officinale exosome has the antioxidant function, the miR-146a and the miR-124 have the synergistic anti-inflammatory function, the dendrobium officinale exosome provides the delivery carrier for the miR-146a and the miR-124, the stability and the anti-inflammatory function of the miR-146a and the miR-124 are improved, and the pharmaceutical composition EXE-miR-146a-124 for treating the neuritis and the related diseases thereof is finally developed. The invention not only provides a safe and efficient miRNA delivery system, but also endows the miRNA delivery system with neuroprotection and anti-inflammatory effects, and provides a brand new and naturally sourced intervention scheme for treatment of nervous system inflammatory diseases.

The invention provides saCNTF-DSF-LNP composite nanoparticles as well as a preparation method and application of the saCNTF-DSF-LNP composite nanoparticles, and particularly relates to application of the saCNTF-DSF-LNP to preparation of medicines for treating diseases related to optic nerve injury. The method comprises the following steps: S1, preparing self-amplification CNTF RNA, and naming the self-amplification CNTF RNA as saCNTF; s2, preparing lipid nano particles entrapped with the disulfiram DSF; s3, quickly adding the ethanol phase containing the disulfiram DSF-lipid mixture into the aqueous phase containing the saCNTF, and mixing, so that the nanoparticles are formed by self-assembly; s4, purifying the nano particles by using an ultrafiltration centrifugal device to obtain saCNTF-DSF-LNP; the invention provides a preparation method and application of saCNTF-DSF-LNP, the saCNTF-DSF-LNP can inhibit neuroinflammation driven by acute pyroptosis, and continuous neurotrophic support is provided for RGC survival and long-term axon regeneration; according to saCNTF-DSF-LNP, continuous expression of CNTF is achieved through saRNA, efficient targeted delivery is achieved by means of LNP so as to reduce off-target toxicity of DSF, and a new treatment strategy is provided for neuritis and degenerative diseases.

The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and / or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).

The application discloses a sesquiterpene dimer and a preparation method and application thereof, and belongs to the technical field of natural compound extraction. According to the preparation method, dried sesquiterpene dimers are extracted by refluxing with 95% ethanol, and then petroleum ether and ethyl acetate are used for extraction to obtain an extract, which can be obtained by column chromatography and semi-preparative high performance liquid chromatography, so that the method is simple, time and labor are saved, and the yield is higher. The obtained sesquiterpene dimers have high anti-neuritis activity, and have important application prospects for developing new drugs for treating senile dementia.

The present invention relates to novel compounds, more particularly to a class of substituted 4-aryl-pyridine compounds, pharmaceutically active salts, prodrugs and analogues thereof. The compounds described herein are more particularly selective adenosine receptor ligands wherein said ligands may be used for the treatment or prophylaxis of disorders including cardiovascular disorders, respiratory disorders, inflammatory and neuroinflammatory disorders, among others.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

The invention provides a pharmaceutical composition for treating herpes zoster as well as a preparation method and application thereof, and belongs to the technical field of medicines. Comprising the following components in parts by weight: 8-15 parts of sticky rice, 8-15 parts of mung beans, 1-3 parts of snake slough, 8-15 parts of flying centipedes, 1-3 parts of realgar and 1-5 parts of borneol. By adding the basic components including the sticky rice, the mung bean, the snake slough, the centipede, the realgar and the borneol, the traditional Chinese medicine composition can achieve the synergistic effects of resisting viruses, relieving pain, diminishing inflammation and the like, effectively relieves the symptoms of rash, pain and the like of herpes zoster, plays a role in neuroinflammation caused by viruses, is relatively mild in medicine property, and is free of toxic and side effects. The medicine is suitable for being used by herpes zoster patients with sensitive skin.

Cembranoid macrocyclic diterpene derivatives, a preparation method therefor, and a use thereof, belonging to the field of medical technology. Disclosed are cembranoid macrocyclic diterpene derivatives, a preparation method therefor, and a use thereof. In the present invention, a series of cembranoid macrocyclic diterpene derivatives are obtained by means of column chromatography and high-performance liquid chromatography separation of an extract from Croton oleifera. Said derivatives are capable of inhibiting LPS-induced NO release in BV-2 cells and have great potential for the preparation of a medicament for neuritis-related diseases.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

The invention belongs to the technical field of medicines, and discloses a C32 cycloartane triterpenoid compound containing 3-ketone carbonyl as well as a preparation method and application of the C32 cycloartane triterpenoid compound. The method comprises the following steps: enriching triterpenoids by utilizing various separation technologies and means, taking pond fir fallen leaves as a separation target and utilizing a molecular sieve principle of gel, then sequentially carrying out silica gel column chromatography and ODS column chromatography separation to obtain a target component, and further purifying to obtain the C32 cycloartane triterpenoids with 3-ketocarbonyl groups. An in-vitro anti-neuritis experiment proves that the C32 cycloartane type triterpenoid with the 3-site keto-carbonyl group has remarkable anti-neuritis activity, can be used as an active ingredient of an anti-neuritis medicine, and has wide application.

The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and / or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R 1 is COOR 4, (CH 2 ) n COOR 4, SO 3 H, (CH 2 ) n SO 3 H or CONH-R 10; one of R 2 and R 3 is H and the other is R 5.

The present disclosure provides methods for treating an inflammatory disease or disorder, wherein the inflammatory disease or disorder is a neurodegenerative and / or neuroinflammatory disease or disorder, comprising administration of a GLP-1 receptor agonist (e.g., semaglutide, exendin-4), and an IL-2 protein (e.g., aldesleukin) to a subject. Also presented herein are compositions for use with the methods disclosed herein and kits for administering a GLP-1 receptor agonist (e.g., semaglutide, ex endin-4), and an IL-2 protein (e.g., aldesleukin).

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-6-7-5 ring system beta acid compound, a preparation method thereof and application of the novel 5-6-7-5 ring system beta acid compound in neuroinflammation resistance. The novel 5-6-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and has a good anti-neuroinflammation effect; the compound can be used for developing drugs for treating neuroinflammation related diseases, including but not limited to depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, optic neuromyelitis, peripheral neuritis and the like.

The invention discloses a kind of abietane type diterpene and its preparation method and application, belong to the field of traditional Chinese medicine extraction and separation, natural medicine chemistry and medical technology. The preparation method of abietane type diterpene comprises the following steps: (1) the whole herb of dried Prunella vulgaris is crushed and extracted with 95% ethanol reflux to obtain an ethanol extract; (2) the ethanol extract is concentrated under reduced pressure to remove alcohol, and the solvent is recovered to obtain a crude extract of Prunella vulgaris; (3) the crude extract is chromatographed on AB‑8 macroporous resin, eluted with 60% and 80% methanol in sequence, and then subjected to LH‑20 gel column chromatography, and then obtained after solvent elution and / or recrystallization. The abietane type diterpene extracted from Prunella vulgaris by the present invention can effectively inhibit the death of nerve cells by anti-oxidative stress, thereby effectively inhibiting neuritis and combating neurodegenerative diseases.

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib as an active ingredient and, in particular, to: a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib or a salt thereof as an active ingredient; and a health functional food for the prevention or amelioration of degenerative brain diseases. Abemaciclib according to the present invention has excellent activity of inhibiting an inflammatory cytokine, i.e., COX-2, IL-1β, IL-6, or iNOS in brain neurons, has excellent activity of inhibiting TLR4 signaling related to inflammatory responses and inhibiting the level of p-STAT3, can inhibit the activity of microglia or astrocytes by LPS, also has the activities of inhibiting amyloid plaques, increasing the number of dendrites, and inhibiting the phosphorylation of tau protein, and can improve the long-term memory of mice with induced degenerative brain diseases. Therefore, abemaciclib of the present invention is effective in use as an active ingredient of medicines and health functional foods for preventing, ameliorating, or treating degenerative brain diseases or neuroinflammatory diseases.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention discloses an acetamine-type sesquiterpene compound, its preparation method, and its applications, belonging to the field of natural compound extraction technology. The preparation method involves extracting dried *Elsholtzia ciliata* by reflux with 95% ethanol, followed by petroleum ether extraction to obtain an extract. The extract can be obtained by column chromatography and semi-preparative high-performance liquid chromatography. The method is simple, time-saving, labor-saving, and yields higher results. Furthermore, the obtained acetamine-type sesquiterpene compound exhibits high anti-neuritis activity, showing significant application potential for developing new drugs to treat neuritis-related diseases.

The application provides an aaptamine alkaloid and a preparation method and application thereof. The aaptamine alkaloid has a structure shown in formula I. The aaptamine alkaloid can significantly inhibit LPS-induced BV2 cell NO production, and inhibit expression of inflammatory factors IL-6, IL-1beta and TNF-alpha, and has an anti-neuroinflammatory effect.

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of divalent metal lactates in the preparation of products for preventing, improving, repairing, and treating nerve damage. Preferably, the divalent metal lactate comprises a combination of one or more of calcium lactate, magnesium lactate, zinc lactate, and ferrous lactate. The present invention provides a new treatment for repairing central and peripheral nerve damage, and has broad application prospects in the treatment and repair of central nervous system damage caused by trauma, or peripheral neuritis or peripheral nerve paresthesia caused by viruses, diabetes, chemotherapy drugs, and other causes.